Obagi Medical Products, Inc. (OMPI) Cash Flow Statement

Click line-items for a historical chart and %

Net income	9.38M
Depreciation and amortization	1.18M
(Gain) loss on disposal of assets	0
Loss on dissolution of foreign subsidiary
Impairment of intangible asset	70K
Charges related to the exit of manufacturing plant
(Recovery of) provision for doubtful accounts	24K
Provision for Texas sales returns and allowances
Stock-based compensation expense	1.49M
Accounts receivable	-418K
Income taxes receivable	-1.43M
Inventories	-2.41M
Prepaid expenses and other current assets	-695K
Other assets	-178K
Accounts payable	-145K
Accrued liabilities	1.74M
Other long-term liabilities	-94K
Net cash provided by operating activities	6.79M
Purchases of property and equipment	-2.22M
Disposal of property and equipment	0
Purchase of other intangible assets	-131K
Maturity of short-term investments
Net cash (used in) provided by investing activities	-2.35M
Principal payments on capital lease obligations	-8K
Proceeds from exercise of stock options	1.83M
Net cash provided by financing activities	-17.99M
Effect of exchange rate changes on cash and cash equivalents
Net increase in cash and cash equivalents	-13.56M
Cash and cash equivalents at beginning of period	35.05M
Cash and cash equivalents at end of period	21.49M

Entities mentioned with OMPI

View All Entities